SYNOVIAL AND SERUM LEVELS OF METHOTREXATE DURING METHOTREXATE THERAPY OF RHEUMATOID ARTHRITIS
- 1 October 1989
- journal article
- research article
- Published by Oxford University Press (OUP) in Rheumatology
- Vol. 28 (5) , 422-423
- https://doi.org/10.1093/rheumatology/28.5.422
Abstract
Methotrexate (MTX) levels were studied following intravenous MTX in both serum and synovial fluid (SF) of rheumatoid arthritis patients. Two hours after injection serum MTX levels were higher than those of SF. At 24 hours SF levels of MTX exceeded those of the serum, while at 72 hours both blood and SF concentrations were undetectable. The localization of parenteral MTX in the SF may have importance in the understanding of its mechanism and site of action in rheumatoid arthritis.Keywords
This publication has 5 references indexed in Scilit:
- Methotrexate in rheumatoid arthritis: a prospective study in Israeli patients with immunogenetic correlations.Annals of the Rheumatic Diseases, 1988
- The effects of leucovorin (folinic acid) on methotrexate therapy in rheumatoid arthritis patientsArthritis & Rheumatism, 1988
- Immunologic studies of rheumatoid arthritis patients treated with methotrexateArthritis & Rheumatism, 1987
- Methotrexate metabolism analysis in blood and liver of rheumatoid arthritis patients: Association with hepatic folate deficiency and formation of polyglutamatesArthritis & Rheumatism, 1986
- The safety and efficacy of the use of methotrexate in long‐term therapy for rheumatoid arthritisArthritis & Rheumatism, 1986